Drug sponsors have options in both how the new FDA risk programs are structured and how to execute them
Industry response may be to keep more innovations as trade secrets
Data from prior Phase II study showed signs of pridopidine slowing disease progression in patients with amyotrophic lateral sclerosis.
Often mistakenly considered an afterthought, today’s packaging and delivery systems can powerfully affect the safety, efficacy and commercial success of injectables
The Medical Affairs function can play a vital role in today’s product launch process
Specialty drug market success requires patient-focused and therapy-specific channel and services strategies
Control of costs and accounting during clinical trials is a well-known challenge to sponsors. Tools are available
Discerning how and where products are discounted is an expensive headache for manufacturers
While FDA guidance on appropriate medical communication has evolved, US Dept. of Justice attention the practice is intensifying
A host of evaluation methodologies are defining ‘value’ in drug prices
Data drawn from collaborating sources can benefit the patient journey
Personality assessments identify the traits that enable some pharma researchers to ascend to leadership roles in industry
How to prepare for reporting and utilizing published data for business and compliance purposes
These organizations are encouraged to consider all alternatives when planning their packaging, serialization and validation strategies
The geriatric-dominated LTC market is growing, but has unique constraints
Vibhu Tewary offers insight on this market segment, including a behind-the-scenes of what goes into designing a report.
Financial and business changes are driving an evolution in channel management strategies
Sharing clinical data—EvGen—will improve both drug development and health outcomes analysis